Systematic Reviews
Copyright ©The Author(s) 2020.
World J Diabetes. Apr 15, 2020; 11(4): 137-149
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.137
Table 3 Baseline characteristics of participants in the included trials
TrialCountryCentersPatientsSample sizeMale %Mean age YDiabetes%Treatment duration MLost to follow-up %BlindingITT analysis
CHANCE 2013China114Minor ischemic stroke or high-risk TIA517066632130.7Double-blindYes
CHARI-SM 2006Worldwide768CVD or multiple risk factors15603706442280.5Double-blindYes
CREDO 2002United States and Canada99Those would undergo elective PCI2116716226121.1Double-blindYes
CURE 2001Worldwide482ACS without ST-segment elevation12562626423120.1Double-blindYes
POINT 2018Worldwide269Acute ischemic stroke or high-risk TIA488155652734.1Double-blindYes
SPS3 2012Worldwide82Recent symptomatic lacunar infarcts3020636336412.0Double-blindYes